BRAF and metastatic melanoma: In this sense, Gonzalez-Cao et al. [61] in patients with metastatic melanoma BRAFV600E mutated in treatment with BRAF inhibitors analyzed ctDNA by digital PCR (sensitivity of 0.005%) and observed that the presence of ctDNA correlated with the clinical stage, being more likely to detect ctDNA in tumors with visceral disease (61–75%) compared with those patients who only presented skin metastases (20%).